DarioHealth Corp has announced it has entered into a strategic agreement with Sanofi U.S, a global healthcare company.
The multi-year, $30 million-dollar agreement, which is subject to certain contingencies, will help to accelerate commercial adoption of Dario‘s full suite of digital therapies. It is hoped it will drive the expansion of digital health solutions on the Dario platform.
Dario and Sanofi will collaborate on promoting the Dario multi-condition digital therapeutics solution which will significantly increase sales reach in the health plan market. This agreement calls for Sanofi and Dario to develop new or enhanced solutions using the Dario platform and for both companies to generate robust evidence to support future commercialisation in the health plan industry.
Sanofi and Dario US clients
Sanofi selected Dario to leverage its broad suite of digital therapeutics and its ability to engage patients for favourable clinical and financial outcomes as a solution for its U.S commercial clients. Dario’s single platform can help patients manage diabetes, hypertension, weight management, musculoskeletal and behavioural health. It offers Sanofi managed care clients an attractive, easily scalable digital health solution that creates immediate access across a wide range of needs.
Erez Raphael, CEO, DarioHealth said: “We are thrilled to be chosen by Sanofi to expand into the digital health market. We believe that this is the first time that a large biopharmaceutical company and a digital health company are collaborating to commercialize digital health solutions in the U.S. market.
Dario’s proven digital therapeutic solutions and innovative technologies provide the perfect complement to Sanofi’s scientific expertise, market access and scale, creating a foundation for long-term success in support of Sanofi’s goal of expanding into digital health therapies for chronic conditions.”
Gustavo Pesquin, head, U.S. General Medicines, Sanofi said: “Our collaboration with Dario is another step towards accelerating Sanofi’s mission of reversing the course of chronic diseases through the integration of healthcare and technology in a way that gives people the tools to improve their health.
We are excited to help payers realize the potential digital health can bring to the patient experience, and we look forward to continuing to innovate with Dario on the next generation of chronic condition therapies.”
